综述

蛋白酶体抑制剂硼替佐米治疗自身免疫病的研究进展

  • 朱娇丽 潘春峰 张进安
展开
  • 201508 上海,复旦大学附属金山医院内分泌-风湿科

网络出版日期: 2025-08-16

Advance in research on treatment of autoimmune diseases with proteasome inhibitor bortezomib

Expand
  • Department of Endocrinology-Rheumatology, Jinshan Hospital, Fudan University, Shanghai 201508, China

Online published: 2025-08-16

摘要

泛素-蛋白酶体系统是细胞内蛋白降解的主要途径,目前认为这一系统参与多种炎症和自身免疫病的发生,因此,通过阻断泛素调节蛋白降解成为治疗自身免疫病的新方法。此文就蛋白酶体抑制剂硼替佐米治疗自身免疫病的研究进展做一综述。

本文引用格式

朱娇丽 潘春峰 张进安 . 蛋白酶体抑制剂硼替佐米治疗自身免疫病的研究进展[J]. 国际生物制品学杂志, 2014 , 37(1) : 28 -31,48 . DOI: 10.3760/cma.j.issn.1673-4211.2014.01.008

Abstract

 The ubiquitin-proteasome system, which is considered to mediate inflammation and autoimmune diseases, is the main way of protein degradation. Thus, blocking of ubiquitin-mediated protein degradation has become a new way for the treatment of autoimmune diseases. This article reviews studies on proteasome inhibitor bortezomib in the treatment of various autoimmune diseases.
文章导航

/